SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169334

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169334

HER2-Targeted Therapy Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

HER2-targeted therapies treat cancers driven by overexpression or mutation of the human epidermal growth factor receptor 2, a protein that fuels aggressive tumour growth. Since the first antibodies against this target transformed outcomes in breast cancer, the class has expanded to include antibody-drug conjugates, small-molecule tyrosine kinase inhibitors and bispecific antibodies, each attacking the pathway in a different way. In 2026, the market is valued at US$10.19 Bn and is projected to reach US$18.67 Bn by 2033, registering a CAGR of 9.00%. The market is being reshaped by antibody-drug conjugates, which deliver potent chemotherapy directly to tumour cells and are now moving into earlier lines of treatment. At the same time, the definition of HER2-positive disease is widening. Patients with lower levels of HER2 expression, and those with lung, gastric and other cancers, are increasingly eligible for targeted treatment. Competition is intensifying as biosimilars enter older segments and innovative developers, including many from China, bring new molecules forward through licensing partnerships.

Market Insights

The market is segmented by drug class, indication and route of administration. Drug classes include monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors and bispecific antibodies. Antibody-drug conjugates are the fastest-growing class, expanding at a 15.6% CAGR, as their strong efficacy supports use across multiple lines and tumour types. Indications span breast cancer, gastric and gastroesophageal cancer, lung cancer and other cancers. Breast cancer remains the foundation of the market, but lung cancer is the fastest-growing indication at 19.2%, reflecting new treatment options for patients with HER2 alterations in lung tumours. Routes of administration include intravenous, subcutaneous and oral delivery. Oral therapy is the fastest-growing route at 13.4%, supported by tyrosine kinase inhibitors that offer convenience for patients. Competitive dynamics are shifting toward new tumour types and earlier-line treatment, where the largest remaining patient pools lie. Chinese developers are also playing a growing role, licensing innovative HER2 assets to Western pharmaceutical companies and adding to pipeline depth across the class.

Drivers

Two high-impact drivers underpin growth. The first is the adoption of antibody-drug conjugates in earlier lines of therapy. These agents have demonstrated strong results in advanced disease, and clinical evidence is supporting their use earlier in the treatment pathway, where patients may stay on therapy longer and outcomes can improve substantially. Each move into an earlier line expands the treated population and the duration of treatment. The second driver is expansion into new tumour types and HER2-low disease. Many patients whose tumours express lower levels of HER2 were previously ineligible for targeted therapy, but newer agents have shown benefit in this group, significantly enlarging the addressable population. Growth in lung, gastric and other cancers adds further momentum. These drivers face meaningful restraints. Biosimilar competition and resulting price erosion represent a high-impact restraint, particularly for established monoclonal antibodies. Toxicity concerns and high treatment costs form a medium-impact restraint, as some therapies carry serious side effects and payers scrutinise the cost of long treatment courses.

Business Opportunity

HER2-low and non-breast cancers form a new patient revenue pool. The recognition that tumours with low HER2 expression can respond to targeted therapy has opened treatment to a large group of patients who previously had few targeted options. Beyond breast cancer, lung, gastric and other tumours with HER2 alterations offer additional populations, and the rapid growth of lung cancer as an indication shows how quickly these segments can develop. Companies with strong diagnostic partnerships and clinical programmes in these areas are well positioned to capture this demand. A second opportunity lies in an innovation revenue pool built on bispecific antibodies, next-generation antibody-drug conjugates and subcutaneous formulations. Bispecifics can bind two sites on the receptor for stronger blockade, while newer conjugates aim to improve the balance between efficacy and toxicity. Subcutaneous forms reduce infusion time and can shift treatment to more convenient settings. Developers that combine these advances with clear clinical differentiation can defend against biosimilar pressure and command premium pricing.

Region Analysis

North America leads the market with a 41.2% share in 2026. High cancer treatment spending, rapid uptake of new targeted therapies, strong clinical trial activity and broad access to biomarker testing support the region's leading position, and new antibody-drug conjugates often launch there first. Europe is a major market with established breast cancer care pathways and wide use of HER2 testing, although national pricing negotiations and early biosimilar adoption weigh on value growth for older agents. Asia Pacific is an important growth market, supported by large patient populations and improving access to innovative oncology medicines. The data does not identify a fastest-growing region, but China is the fastest-growing country, expanding at a 12.6% CAGR through 2033, driven by expanding oncology care, faster approvals and a vibrant domestic developer base. Latin America shows rising demand as access programmes and biosimilars widen availability. The Middle East and Africa is developing gradually, with use concentrated in specialist cancer centres and wealthier healthcare systems.

Key Players

  • Roche
  • AstraZeneca
  • Daiichi Sankyo
  • Pfizer
  • Jazz Pharmaceuticals
  • Boehringer Ingelheim
  • Bayer
  • Puma Biotechnology
  • Celltrion
  • Samsung Bioepis

Segmentation

By Drug Class:

  • Monoclonal Antibodies
  • Antibody-Drug Conjugates
  • Tyrosine Kinase Inhibitors
  • Bispecific Antibodies

By Indication:

  • Breast Cancer
  • Gastric & Gastroesophageal Cancer
  • Lung Cancer
  • Other Cancers

By Route of Administration:

  • Intravenous
  • Subcutaneous
  • Oral

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global HER2-Targeted Therapy Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 3.1. Global HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.1.1. Monoclonal Antibodies
    • 3.1.2. Antibody-Drug Conjugates
    • 3.1.3. Tyrosine Kinase Inhibitors
    • 3.1.4. Bispecific Antibodies
  • 3.2. Global HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 3.2.1. Breast Cancer
    • 3.2.2. Gastric & Gastroesophageal Cancer
    • 3.2.3. Lung Cancer
    • 3.2.4. Other Cancers
  • 3.3. Global HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.3.1. Intravenous
    • 3.3.2. Subcutaneous
    • 3.3.3. Oral
  • 3.4. Global HER2-Targeted Therapy Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 4.1. North America HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.1.1. Monoclonal Antibodies
    • 4.1.2. Antibody-Drug Conjugates
    • 4.1.3. Tyrosine Kinase Inhibitors
    • 4.1.4. Bispecific Antibodies
  • 4.2. North America HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 4.2.1. Breast Cancer
    • 4.2.2. Gastric & Gastroesophageal Cancer
    • 4.2.3. Lung Cancer
    • 4.2.4. Other Cancers
  • 4.3. North America HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.3.1. Intravenous
    • 4.3.2. Subcutaneous
    • 4.3.3. Oral
  • 4.4. North America HER2-Targeted Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 4.4.2. U.S. HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 4.4.3. U.S. HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 4.4.4. Canada HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 4.4.5. Canada HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 4.4.6. Canada HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 5.1. Europe HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.1.1. Monoclonal Antibodies
    • 5.1.2. Antibody-Drug Conjugates
    • 5.1.3. Tyrosine Kinase Inhibitors
    • 5.1.4. Bispecific Antibodies
  • 5.2. Europe HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 5.2.1. Breast Cancer
    • 5.2.2. Gastric & Gastroesophageal Cancer
    • 5.2.3. Lung Cancer
    • 5.2.4. Other Cancers
  • 5.3. Europe HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.3.1. Intravenous
    • 5.3.2. Subcutaneous
    • 5.3.3. Oral
  • 5.4. Europe HER2-Targeted Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.2. Germany HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.3. Germany HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.4. Italy HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.5. Italy HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.6. Italy HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.7. France HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.8. France HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.9. France HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.10. U.K. HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.11. U.K. HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.12. U.K. HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.13. Spain HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.14. Spain HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.15. Spain HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.16. Russia HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.17. Russia HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.18. Russia HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 5.4.19. Rest of Europe HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 5.4.20. Rest of Europe HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 5.4.21. Rest of Europe HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.1.1. Monoclonal Antibodies
    • 6.1.2. Antibody-Drug Conjugates
    • 6.1.3. Tyrosine Kinase Inhibitors
    • 6.1.4. Bispecific Antibodies
  • 6.2. Asia Pacific HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 6.2.1. Breast Cancer
    • 6.2.2. Gastric & Gastroesophageal Cancer
    • 6.2.3. Lung Cancer
    • 6.2.4. Other Cancers
  • 6.3. Asia Pacific HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.3.1. Intravenous
    • 6.3.2. Subcutaneous
    • 6.3.3. Oral
  • 6.4. Asia Pacific HER2-Targeted Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.2. China HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.3. China HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 6.4.4. Japan HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.5. Japan HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.6. Japan HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 6.4.7. South Korea HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.8. South Korea HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.9. South Korea HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 6.4.10. India HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.11. India HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.12. India HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 6.4.13. Southeast Asia HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.14. Southeast Asia HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.15. Southeast Asia HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 6.4.16. Rest of SAO HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 6.4.17. Rest of SAO HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 6.4.18. Rest of SAO HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 7.1. Latin America HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.1.1. Monoclonal Antibodies
    • 7.1.2. Antibody-Drug Conjugates
    • 7.1.3. Tyrosine Kinase Inhibitors
    • 7.1.4. Bispecific Antibodies
  • 7.2. Latin America HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 7.2.1. Breast Cancer
    • 7.2.2. Gastric & Gastroesophageal Cancer
    • 7.2.3. Lung Cancer
    • 7.2.4. Other Cancers
  • 7.3. Latin America HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.3.1. Intravenous
    • 7.3.2. Subcutaneous
    • 7.3.3. Oral
  • 7.4. Latin America HER2-Targeted Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 7.4.2. Brazil HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 7.4.3. Brazil HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 7.4.4. Mexico HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 7.4.5. Mexico HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 7.4.6. Mexico HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 7.4.7. Argentina HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 7.4.8. Argentina HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 7.4.9. Argentina HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 7.4.10. Rest of LATAM HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 7.4.11. Rest of LATAM HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 7.4.12. Rest of LATAM HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa HER2-Targeted Therapy Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa HER2-Targeted Therapy Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Antibody-Drug Conjugates
    • 8.1.3. Tyrosine Kinase Inhibitors
    • 8.1.4. Bispecific Antibodies
  • 8.2. Middle East & Africa HER2-Targeted Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 8.2.1. Breast Cancer
    • 8.2.2. Gastric & Gastroesophageal Cancer
    • 8.2.3. Lung Cancer
    • 8.2.4. Other Cancers
  • 8.3. Middle East & Africa HER2-Targeted Therapy Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.3.1. Intravenous
    • 8.3.2. Subcutaneous
    • 8.3.3. Oral
  • 8.4. Middle East & Africa HER2-Targeted Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 8.4.2. GCC HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 8.4.3. GCC HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 8.4.4. South Africa HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 8.4.5. South Africa HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 8.4.6. South Africa HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 8.4.7. Egypt HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 8.4.8. Egypt HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 8.4.9. Egypt HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 8.4.10. Nigeria HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 8.4.11. Nigeria HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 8.4.12. Nigeria HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
    • 8.4.13. Rest of Middle East HER2-Targeted Therapy Market Outlook, by Drug Class, 2020-2033
    • 8.4.14. Rest of Middle East HER2-Targeted Therapy Market Outlook, by Indication, 2020-2033
    • 8.4.15. Rest of Middle East HER2-Targeted Therapy Market Outlook, by Route of Administration, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Roche
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. AstraZeneca
    • 9.4.3. Daiichi Sankyo
    • 9.4.4. Pfizer
    • 9.4.5. Jazz Pharmaceuticals
    • 9.4.6. Boehringer Ingelheim
    • 9.4.7. Bayer
    • 9.4.8. Puma Biotechnology
    • 9.4.9. Celltrion
    • 9.4.10. Samsung Bioepis

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!